Shares of Tekmira soar after first U.S. Ebola case confirmed


Shares of Tekmira (TSX:TKM, Nasdaq:TKMR) are soaring in after market trading after news broke of the first diagnosis of Ebola in the United States. A patient at Dallas’s Texas Health Presbyterian Hospital has tested positive for Ebola, and is currently being treated. The Centers for Disease Control and Prevention this afternoon confirmed that the infected […]

Sensing An Opportunity: Opsens Poised To Enter Growing Cardiac Market


Back when I was a drug rep, I spent a few days shadowing a cardiologist and was fortunate to spend some time in the cardiac catheterization lab (cath lab). Those were the heady days of drug eluding stents, where companies like Angiotech were soaring on the wide utilization of stents for coronary artery disease. Things […]

Take a wait-and-see approach to Merus Labs, says Paradigm

merus labs chart

The resignation of CEO Elie Farah is a short-term negative for Merus Labs (TSX:MSL), but the company’s lucrative platform remains, says Paradigm Capital analyst Alan Ridgeway. Shares of Merus fell by more than 22% yesterday after Farah’s sudden resignation as CEO and from the company’s board. The company said Barry Fishman, an industry veteran previously […]

Merus Labs tumbles after CEO resignation


Shares of Merus Labs (TSX:MSL) fell more than 22% today after CEO Elie Farah’s sudden resignation. Barry Fishman, an industry veteran previously with Teva Canada and Eli Lilly, will assume the role of interim CEO. Fishman was previously a senior advisor to the company. Despite today’s action, Merus looked to assure investors of its continuity. […]

Bioniche Extends Cash Runway In Advance of FDA Decisions & Submissions


Bioniche Life Sciences (TSX:BNC) was heavily traded last week after the company announced its final prospectus had been filed for a $5-million equity raise. The additional funds give the company financial runway into 2016, by which time it expects to have heard from FDA on the potential approval of its experimental drug mycobacterial cell wall-nucleic […]

Paradigm lowers target on Oncolytics, but says stock is still a buy


The results from Oncolytics’ (TSX:ONC) U.S. Phase Two pancreatic cancer study were “mixed” says Paradigm Capital analyst Alan Ridgeway, but the company’s lead product REOLYSIN still has a multi-billion dollar market opportunity and several near term catalysts. Yesterday, Oncolytics released patient data from its U.S. randomized Phase Two Pancreatic Cancer Study. The market response was […]

Oncolytics Slides After Pancreatic Study Results


Yesterday, after market close, Oncolytics (TSX:ONC, Nasdaq:ONCY) delivered underwhelming data from a Phase II cancer study, causing its stock to swoon today. The U.S. National Cancer Institute sponsored study evaluated Oncolytics experimental therapy, REOLYSIN, in combination with paclitaxel versus a control arm that included carboplatin and paclitaxel in patients with recurrent or metastatic pancreatic cancer. […]

Shares of Merus Labs rise after acquiring Sintrom from Novartis AG


Shares of Merus Labs (TSX:MSL) are up this morning on heavier than normal volume after the company announced that one of its wholly owned subsidiaries had acquired, in certain European countries, the right to manufacture, market and sell Sintrom, an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom has been available for […]